Heart Failure Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
نویسندگان
چکیده
Linda B. Piller, MD, MPH; Sarah Baraniuk, PhD; Lara M. Simpson, PhD; William C. Cushman, MD; Barry M. Massie, MD; Paula T. Einhorn, MD, MS; Suzanne Oparil, MD; Charles E. Ford, PhD; James F. Graumlich, MD; Richard A. Dart, MD; David C. Parish, MD, MPH; Tamrat M. Retta, MD, PhD; Aloysius B. Cuyjet, MD, MPH; Syed Z. Jafri, MD; Curt D. Furberg, MD, PhD; Mohammad G. Saklayen, MBBS; Udho Thadani, MD; Jeffrey L. Probstfield, MD; Barry R. Davis, MD, PhD; for the ALLHAT Collaborative Research Group
منابع مشابه
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
BACKGROUND In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, practice-based, active-control, comparative effectiveness trial in high-risk hypertensive participants, risk of new-onset heart failure (HF) was higher in the amlodipine (2.5-10 mg/d) and lisinopril (10-40 mg/d) arms compared with the chlorthalidone (12.5-25 mg/d) ...
متن کاملValidation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
BACKGROUND: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in high-risk hypertensive participants initially randomized to a diuretic (chlorthalidone) versus each of three alternative antihypertensive drugs: alpha-adrenergic blocker (doxaz...
متن کاملRIGINAL INVESTIGATIONS athogenesis and Treatment of Kidney Disease Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Mahboob Rahman, MD, MS, Charles Baimbridge, MS, Barry R. Davis, MD, PhD, Joshua Barzilay, MD, Jan N. Basile, MD, Mario A. Henriquez, MD, Anne Huml, MD, Nelson Ko...
متن کاملAsking the shisha question.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J...
متن کاملDoxazosin and congestive heart failure.
Congestive heart failure (CHF) is the most devastating cardiac sequella of long-standing hypertension. Recent data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF to be twice as high with doxazosin than with chlorthalidone. Although some questions remain regarding the diagnosis and mortality of CHF in the doxazosin arm and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011